Testosterone therapy and prostate cancer

Alexander W. Pastuszak, Katherine M. Rodriguez, Taylor M. Nguyen, Mohit Khera*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


The use of exogenous testosterone to treat hypogonadism in the men with a history of prostate cancer (CaP) remains controversial due to fears of cancer recurrence or progression. Due to the detrimental impact of hypogonadism on patient quality of life, recent work has examined the safety of testosterone therapy (TTh) in men with a history of CaP. In this review, we evaluate the literature with regards to the safety of TTh in men with a history of CaP. TTh results in improvements in quality of life with little evidence of biochemical recurrence or progression in men with a history of CaP, or de novo cancer in unaffected men. An insufficient amount of evidence is currently available to truly demonstrate the safe use of TTh in men with low risk CaP. In men with high-risk cancer, more limited data suggest that TTh may be safe, but these findings remain inconclusive. Despite the historic avoidance of TTh in men with a history of CaP, the existing body of evidence largely supports the safe and effective use of testosterone in these men, although additional study is needed before unequivocal safety can be demonstrated.

Original languageEnglish (US)
Pages (from-to)909-920
Number of pages12
JournalTranslational Andrology and Urology
Issue number6
StatePublished - 2016


  • Hormone replacement
  • Hypogonadism
  • Prostate cancer (CaP)
  • Prostatectomy
  • Radiation therapy
  • Testosterone

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology


Dive into the research topics of 'Testosterone therapy and prostate cancer'. Together they form a unique fingerprint.

Cite this